Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
Lisa Sigl
Advertisement
Director, Executive Insight, Healthcare Consultants
Articles by Lisa Sigl
How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
2
Beyond the Molecule: The New Competitive Battlefield in Oncology
3
FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax
4
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
5